Abstract: Described herein are compounds of the formulae (I)-(III) as well as pharmaceutical compositions comprising such compounds and methods for using such compounds/pharmaceutical compositions for treating Alzheimer's disease.

Abstract: The instant invention is related with new perimidine derivatives synthesized via direct condensation between naphthalene-1,8-diamine and itaconic or citraconic anhydrides at low temperature. The targeting itaco-perinone (IP) molecule formed via double low temperature cyclization has fluorescence properties emitting white light intensively. Besides, 9-methylene-8H-pyrrolo[1,2-a]perimidin-10(9H)-one is copolymerizable with several kind of organic monomer compounds via free radical mechanism maintaining the ability to emit white light even within the polymer film.

Abstract: Embodiments of the invention include methods of treating, preventing, and/or reducing the risk of fibrosis in an individual in need thereof. In some embodiments, particular small molecules are employed for treatment, prevention, and/or reduction of the risk of fibrosis. In at least particular cases, the small molecules are inhibitors of STAT3.

Abstract: A benzene sulphonamide compound of formula I or one of its addition salts with pharmaceutically acceptable acids, for its use in a method for treating a pathology linked to an excessive effect of TNF-alpha and for its use in a method for treating the human or animal body as a direct inhibitor of TNF-alpha.

Abstract: The present invention relates to diazabenzo[de]anthracen-3-one compounds which inhibit poly(ADP-ribose) polymerase (“PARP”), compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein.

Abstract: A straightforward single step method for the preparation and/or production of substituted quinazolines is disclosed, wherein said quinazolines preferably contain one substituent at position 4, and may contain other functional groups at various positions, such as 5, 6, 7, and/or 8 of quinazolines. In addition, the extension of this new method leads to the formation of different type of heterocyclic aromatic compounds, that include but are not limited to perimidines, anthrapyrimidin-7-ones (also known as anthrapyrimidinones), anthra[1,9:5,10]dipyrimidines (also known as quinazoline[5,4-ef]perimidines) and benzo[e]-pyrimido[4,5,6-gh]pyrimidines.

Abstract: The present invention relates to electronic devices, especially electroluminescent devices, comprising azapyrenes of formula (I), or formula (III), wherein Y1, Y2, Y3, Y4, X1, X2 and X3 are independently each other N, or CR4, with the proviso that at least one of the groups X1, X2 and X3 is a group CR4, R1 is hydrogen, F, —SiR100R101R102, or an organic substituent, R4 is hydrogen, F, —SiR100R101R102, or an organic substituent, or any of the substituents R1, R1? and R4, which are adjacent to each other, together form an aromatic, or heteroaromatic ring, or ring system, which can optionally be substituted, m is an integer of 1 to 6, and R100, R101 and R102 are independently of each other a C1-C8alkyl group, a C6-C24aryl group, or a C7-C12aralkyl group, which may optionally be substituted, and Q is a linking group; with the proviso that in the compound of formula (III) at least one of the substituents R1, or R4 is a group Q; especially as host for phosphorescent emitters, electron transporting materials, or emit

Abstract: The present invention relates to diazabenzo[de]anthracen-3-one compounds which inhibit poly(ADP-ribose) polymerase (“PARP”), compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein.

Abstract: The invention provides compounds that inhibit protein kinases, prodrugs of the compounds, intermediates and methods of synthesizing the compounds and/or prodrugs, pharmaceutical compositions including the compounds and/or prodrugs and methods of using the compounds and/or prodrugs in a variety of contexts, including, for example, in the treatment and/or prevention of various diseases that are responsive to protein kinase inhibition and/or that are mediated, at least in part, by inappropriate kinase activity.

Abstract: The present invention relates to electronic devices, especially electroluminescent devices, comprising azapyrenes of formula (I), or formula (III), wherein Y1, Y2, Y3, Y4, X1, X2 and X3 are independently each other N, or CR4, with the proviso that at least one of the groups X1, X2 and X3 is a group CR4, R1 is hydrogen, F, —SiR100R101R102, or an organic substituent, R4 is hydrogen, F, —SiR100R101R102, or an organic substituent, or any of the substituents R1, R1? and R4, which are adjacent to each other, together form an aromatic, or heteroaromatic ring, or ring system, which can optionally be substituted, m is an integer of 1 to 6, and R100, R101 and R102 are independently of each other a C1-C8alkyl group, a C6-C24aryl group, or a C7-C12aralkyl group, which may optionally be substituted, and Q is a linking group; with the proviso that in the compound of formula (III) at least one of the substituents R1, or R4 is a group Q; especially as host for phosphorescent emitters, electron transporting materials, or emit

Abstract: The present invention relates to diazabenzo[de]anthracen-3-one compounds which inhibit poly(ADP-ribose) polymerase (“PARP”), compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein.

Abstract: A water-soluble dye of the Formula (1): D1-L-D2 ??Formula (1) wherein D1 and D2 each independently is an anthrapyridone, anthrapyrazole, anthrapyrimidine or anthrapyrimidone group; and L is a single covalent bond or a linking group which permits at least partial delocalisation of electrons between D1 and D2, compositions and inks containing the dye, and printing processes, printed material and ink-jet printer cartridges based on use of the dye.

Abstract: This invention concerns quinazoline analogs of Formula I: where an A group is bonded to at least one of the carbons at the 5, 6, 7 or 8 position of the bicyclic ring, and the ring is substituted by up to three independent R3 groups. The invention also includes methods of using these compounds as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

Abstract: A subject-matter of the invention is the compounds of general formula (I) in which X represents a hydrogen or halogen atom; R1 represents a hydrogen atom or a (C1-C4)alkyl group; R2 and R3 each represent, independently of one another, a hydrogen atom or a (C1-C4)alkyl group or else R2 and R3 form, with the nitrogen atom which carries them, a pyrrolidinyl, piperidinyl, morpholinyl or 4-alkylpiperazinyl group; and Het represents a heteroaromatic group of pyridinyl, 1-oxidopyridinyl, quinolinyl, isoquinolinyl, pyrimidinyl, pyrazinyl or pyridazinyl type, it being possible for the heteroaromatic group to carry one or more halogen atoms and/or one or more (C1-C4)alkyl or (C1-C4)alkoxy groups; in the form of bases, of addition salts with acids, of solvates or of hydrates, the pharmaceutical compositions comprising them, processes for their preparation and synthetic intermediates.

Abstract: Substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

Abstract: Tri-heterocyclic compound of formula (I) wherein each of W, X and Y is carbon or nitrogen; each of U and Z is CR2, NR13, nitrogen, oxygen, sulfur etc.; A ring is carbocyclic ring, heterocyclic ring; R1 is alkyl, alkenyl, alkynyl, NR4R5, OR6 etc.; R3 is carbocyclic ring, heterocyclic ring; and a pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical comprising them as an active ingredient. A compound of formula (I) is useful, in order to possess corticotropin releasing factor receptor antagonistic activity, for the prevention and/or treatment of depression, anxiety, eating disorder, posttraumatic stress disorder, peptic ulcer, irritable bowl syndrome, Alzheimer's disease, drug addiction or alcohol dependence syndrome etc.

Abstract: A dye is disclosed, which is represented by the following formula: wherein Z is an atomic group necessary to form a 6-membered nitrogen containing aromatic ring; R11 is a hydrogen bonding group; R12, R13 and R14 are independently a hydrogen atom or a substituent; n11 and n13 are each an integer of 1 to 4; n12 is an integer of 1 to 3. There is also disclosed an ink for ink jet printing which contains the foregoing dye.

Abstract: This invention relates to therapeutic methods for treatment or prevention of tissue damage resulting from ischemia in mammals.

Abstract: The invention relates to a process and intermediates for the preparation of enantiomerically pure cycloalkanoindolecarboxylic acids and azaindolecarboxylic acids and pyrimido[1,2a]indolecarboxylic acids and their activated derivatives, characterized in that the tolyl acetic acid is first esterified with a chiral alcohol, then diastereoselective substitution at &agr;-carbon atoms is carried out and this product is halogenated in the tolyl group and then reacted with appropriate cycloalkanoindoles, cycloalkanoazaindoles or pyrimido[1,2a]indoles. It is possible by this method to prepare specifically, in high purity, the enantiomerically pure carboxylic acids which are intermediates for valuable medicaments.

Abstract: Compounds of formula (I′), wherein A, R1 to R3 and t are as defined in the disclosure, exhibit COMT enzyme inhibiting activity so that they are useful as COMT inhibitors.

Abstract: Disclosed herein are bridged perinones/quinophthalones of the general formula (I) or tautomeric forms thereof 1

Abstract: Novel isoindoline pigments of the formula (I): ##STR1## in which R.sup.1 is --CN;R.sup.2 is --CN or a saturated or unsaturated, aromatic or non-aromatic, 5- to 7-membered heterocyclic ring system which can be modified by fusion or bridging with other heterocyclic or isocyclic ring systems, the heteroatoms being N, O and/or S;or a group --CO--NR.sup.6 R.sup.7, in which R.sup.6 and R.sup.7 are identical or different and are hydrogen or C.sub.1 -C.sub.4 -alkyl;or a group --CO--NR.sup.6 R.sup.8, in which R.sup.8 is a saturated or unsaturated, aromatic or non-aromatic, 5- to 7-membered isocyclic or heterocyclic ring which is unsubstituted or substituted by one to 5 of the following radicals: C.sub.1 -C.sub.4 -alkyl, halogen, trifluoromethyl, C.sub.1 -C.sub.4 -alkoxy, carbomethoxy, carbethoxy, carboxamide, carboxamide substituted by a C.sub.1 -C.sub.4 -alkyl or phenyl group, nitro, C.sub.1 -C.sub.

Abstract: Dyes of the formula ##STR1## in which F is the radical of an indigoid dye, of a benzothioxanthene or of an aromatic dye which contains at least 4 alicyclic and/or heterocyclic, fused six-membered rings and at least two ring keto groups and is not water-soluble, R.sub.1 is a substituted or unsubstituted C.sub.1-4 -alkyl radical, a substituted or unsubstituted cycloalkyl radical, a substituted or unsubstituted aryl radical or a radical of the formula--A--Qwhere A is a substituted or unsubstituted C.sub.1-4 -alkylene radical and Q is a basic radical, which may be quaternised, and R.sub.2 is hydrogen or a substituted or unsubstituted C.sub.1-4 -alkyl radical, or in which R.sub.1 and R.sub.2 together with the ##STR2## group are a phthalimide radical, and R.sub.3 is hydrogen, a substituted or unsubstituted C.sub.1-4 -alkyl radical, a substituted or unsubstituted aryl radical, a C.sub.1-4 -alkoxycarbonyl radical or a N,N-di-C.sub.1-4 -alkylcarboxamide radical and n is 1, 2, 3 or 4.

Abstract: 1-Aryl-2-naphthoylamines of formula I are described ##STR1## wherein R.sub.1 is halogen, nitro, cyano, C.sub.1 -C.sub.6 alkyl that is unsubstituted or mono- or poly-substituted by halogen and/or C.sub.1 -C.sub.3 alkoxy, or is C.sub.3 -C.sub.6 cycloalkyl, OR.sub.4, NR.sub.5 R.sub.6, CO2R.sub.5, CONR.sub.5 R.sub.6 or NHCOR.sub.7, or wherein two adjacent positions in the nucleus are bridged by a methylenedioxy or ethylenedioxy group that is unsubstituted or mono- or poly-substituted by fluorine, wherein further R.sub.4 is hydrogen or C.sub.1 -C.sub.6 alkyl that is unsubstituted or substituted by C.sub.1 -C.sub.3 alkoxy or mono- or poly-substituted by halogen, or is C.sub.3 -C.sub.4 alkenyl, 2-propynyl, 3-halo-2-propynyl, ##STR2## or COR.sub.7, each of R.sub.5 and R.sub.6, independently of the other, is H or C.sub.1 -C.sub.4 alkyl, R.sub.7 is C.sub.1 -C.sub.

Abstract: There are disclosed compounds having the formula ##STR1## where R.sub.1 is hydrogen, loweralkyl or arylloweralkyl;Z is hydrogen, loweralkyl, loweralkoxy, halogen, hydroxy, nitro or trifluoromethyl;Y is O or NR.sub.2, R.sub.2 being hydrogen, loweralkyl or arylloweralkyl; andX is CR.sub.3, CHR.sub.3, C.dbd.O, C.dbd.S or CHN(CH.sub.3).sub.2, R.sub.3 being hydrogen, loweralkyl or aryl;stereo isomers thereof and pharmaceutically acceptable acid addition salts thereof, which are useful for the treatment of various memory dysfunctions characterized by decreased cholinergic function, such as Alzheimer's disease.

Abstract: Liquid-crystalline phenylpyrimidinyl cyclohexanecarboxylates having a smectic phase, a process for their preparation, and their use in liquid-crystal mixtures The phenylpyrimidinyl trans-cyclohexanecarboxylates of the general formula ##STR1## form a smectic C phase besides a relatively broad nematic phase when R.sup.1 denotes an alkyl radical having 10 to 16 carbon atoms, in particular 11 to 16 carbon atoms, or an alkoxy radical having 8 to 14 carbon atoms, and R.sup.2 denotes an alkyl radical having 2 to 9 carbon atoms. They are therefore particularly suitable as components of liquid-crystalline mixtures having a smectic C phase since they induce a relatively broad nematic phase or extend a narrow nematic phase which is present and extend the temperature range of the smectic C phase to low temperatures, but in particular to high temperatures.

Abstract: The invention relates to vattable 2-aryl-4,6-diaminopyrimidines of formula ##STR1## wherein A.sub.1 and A.sub.2 are identical or different vattable radicals, andAr is an aryl radical.These pyrimidines are particularly suitable vat dyes for dyeing or printing textile fibres made from natural or regenerated cellulose. They give light- and wetfast orange, red or violet dyeings.

Abstract: A liquid crystal compound comprising the following general formula (1): ##STR1## where i, j and k individually represent an integer within a range: 1.ltoreq.i.ltoreq.8, 0.ltoreq.j.ltoreq.7, 4.ltoreq.k.ltoreq.14, Ar.sub.1 represents ##STR2## *represents an asymmetric carbon and the compound is required to be optically active. The compound can provide various merits as the chiral substance such as satisfactory optical rotation, capability of inducing twisted arrangement when added to the TN system or phase transition system liquid crystal mixture, and of enlarging the liquid crystal temperature range when added to SmC* liquid crystal mixture.

Abstract: Prepare N-(amidoalkyl)imides by contacting an imide with a 2-oxazoline under reaction conditions, optionally in the presence of a solvent.

Abstract: Indene derivatives have been found to have potent and specific PAF (Platelet-Activating-Factor) antagonistic activities and are thereby useful in the treatment of various diseases or disorders mediated by the PAF, for example, inflammation, cardiovascular disorder, asthma, lung edema, and adult respiratory distress syndrome.

Abstract: The invention relates to chromogenic naphtholactams of the general formula ##STR1## wherein Q is the radical of a couplable compound,X is oxygen or ##STR2## wherein R is hydrogen, lower alkyl or aryl, and W is alkylene, cycloalkylene or a 6-membered isocyclic or heterocyclic aromatic radical which is unsubstituted or substituted or which may contain a fused benzene ring; and each of the ringsA and B independently of the other are unsubstituted or substituted.These compounds are particularly suitable for use as color formers in pressure-sensitive or heat-sensitive recording materials and, depending on the meaning of X and Q, give orange, red, violet and blue colorations.

Abstract: Compounds of the formula (1) ##STR1## wherein n is 1 or 2;R.sub.1 represents a hydrogen or a halogen atom, a C.sub.1 -C.sub.4 alkyl group, a --CN group, a --CONH.sub.2 group or a --COOR.sub.8 group, wherein R.sub.8 represents hydrogen or a C.sub.1 -C.sub.6 alkyl group, unsubstituted or substituted by di(C.sub.1 -C.sub.4) - alkylamino;each of R.sub.2, R.sub.3 and R.sub.4 independently represents a hydrogen or a halogen atom, a C.sub.1 -C.sub.4 alkyl group, a C.sub.1 -C.sub.4 alkoxy group or a C.sub.3 -C.sub.4 alkenyloxy group;A completes a bond, thereby providing a double bond or, when R.sub.1 is --COOR.sub.8 wherein R.sub.8 is as defined above, A may represent also a --CH.sub.2 -- group, thereby providing a cyclopropane ring fused to the pyrido ring;R is (a) furyl, thienyl or pyridyl; or(b) a group of formula ##STR2## wherein each of R.sub.5, R.sub.6 and R.sub.7 represents, independently, a hydrogen or a halogen atom, hydroxy, formyloxy, C.sub.2 -C.sub.8 alkanoyloxy, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.

Abstract: Heterocyclic compounds of the formula ##STR1## wherein R.sub.1 denotes a substituent,R.sub.2 denotes an optionally substituted carbocyclic-aromatic or heterocyclic-aromatic radical andn denotes 0, 1, 2, 3 or 4, and azo colorants of the formula ##STR2## wherein D denotes the radical of an aromatic or hetero-aromatic amine which is free from sulphonic acid groups,p denotes an integer, preferably 1 or 2, andR.sub.1, R.sub.2 and n have the meaning mentioned in claim 1, processes for the preparation of the heterocyclic compounds and of the azo colorants, and the use of the azo colorants as pigments.

Abstract: Derivatives of fluorenes and fluoranthenes, in the form of racemates or of enantiomers, of the formula (I) ##STR1## in which n is 1 or 2, R.sub.1 is a hydrogen or halogen atom or an alkyl or alkoxy radical, R.sub.2 is a hydrogen atom or an alkyl, cycloalkyl, cycloalkylalkyl, benzyl, halogenobenzyl, alkylbenzyl, alkoxybenzyl, acyl, alkoxycarbonyl or alkylaminocarbonyl radical, R.sub.3 is a hydrogen atom or an alkyl radical, R.sub.4 is a hydrogen atom or an alkyl, acyl or aroyl radical, the alkyl and alkoxy radicals or parts of radicals having from 1 to 4 carbon atoms and pharmaceutically acceptable acid addition salts thereof, are therapeutically valuable as anti-anoxia and psychotropic agents.

Abstract: Imidazo- and pyrimido[2,1-b]quinazolines of the formula, ##STR1## wherein R.sub.1 and R.sub.2 are independently hydrogen, halogen, trifluoromethyl, nitro, C.sub.1-4 alkyl or C.sub.1-4 alkoxy, or R.sub.1 and R.sub.2 may together represent methylenedioxy; R.sub.3 is hydrogen, C.sub.1-4 alkyl, phenyl or substituted phenyl of the formula, ##STR2## (wherein R is halogen, C.sub.1-4 alkyl or C.sub.1-4 alkoxy); R.sub.4 is hydrogen, C.sub.1-4 alkyl or aralkyl; and A is C.sub.2-3 alkylene wich may be optionally substituted by one or two C.sub.1-2 alkyl radicals, and pharmaceutically acceptable acid addition salts thereof, are prepared by reacting a compound of the formula, ##STR3## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4 and A are as defined above; and X is oxygen or sulfur, with a halogenating agent at a temperature of about 30.degree. C. to about 180.degree. C. In the above imidaxo- and pyrimido[2,1-b]quinazolines, those having C.sub.1-4 alkyl, or ##STR4## as R.sub.

Abstract: Compounds of the formula ##STR1## where A is a heterocyclic group containing a pyridone moiety and R to R.sup.5 are each hydrogen or substituents conventionally encountered in dyes. The compounds are eminently suitable for coloring resins and for dyeing textile materials, particularly polyester textile materials.

Abstract: Polycyclic chlorinated amines resulting from cycloadditions useful as insecticides.